We present a case of a 62-year-old male patient with pleomorphic adenoma and painless solid mass in his right eye. Computerized tomography demonstrated a mass with a diameter of 2.5 cm located in the right lacrimal gland. The mass was removed completely by combined orbitofrontal craniotomy through a transcranial approach. Histopathologic examination revealed pleomorphic adenoma of the lacrimal gland. Orbital tumors originate primarily from vascular, muscle, cartilage, neural tissues, lacrimal glands and lymphoid structures. Five percent of all intraorbital masses originate from the lacrimal gland. Pleomorphic adenoma presents as a painless and slowly growing mass and also as exophthalmoses. Pleomorphic adenoma has a high morbidity. Morbidity increases due to the total displacement of the tumor without its capsule and incisional biopsy for the purpose of diagnosis. The success of the treatment depends on the removal of the tumor with its capsule.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853974 | PMC |
http://dx.doi.org/10.1093/jscr/rjt089 | DOI Listing |
Am J Otolaryngol
December 2024
Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Purpose: We examined operative efficiency, rate of facial nerve paresis, and post-operative outcomes in patients undergoing retrograde (RGD) vs anterograde dissection (AGD) of the facial nerve controlling for tumor location.
Methods: Single-institution, retrospective analysis of patients with benign parotid tumors undergoing superficial parotidectomy with facial nerve dissection over a six-year period. Operative and pathology reports were reviewed to classify tumor size, location in relation to facial nerve branches, and technique for facial nerve dissection.
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFRadiol Case Rep
February 2025
Department of Radiology, National Institute of Oncology, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Rabat, Morocco.
Pleomorphic adenoma (PA) is the most common benign histological form of salivary gland tumors, particularly in the parotid gland, primarily affecting women between the ages of 40 and 60. However, its occurrence in the trachea is very rare. This article reports the case of a 48-year-old woman presenting with progressive dyspnea and weight loss, initially suspected of having a pulmonary embolism.
View Article and Find Full Text PDFBMC Oral Health
December 2024
Department of Oral and Maxillofacial Surgery, Xuchang Central Hospital, Henan, China.
Objectives: This study explored the suitability of local anaesthesia with conscious sedation for parotid gland tumour surgery.
Methods: Three hundred sixty-four medical records were reviewed to gather data on several key aspects for retrospective analysis. These included age, incision length, operation time, tumour size, NNIS score, ASA score, and pathology.
Int J Mol Sci
November 2024
Department of Otolaryngology, Academy of Applied Medical and Social Sciences, 82-300 Elblag, Poland.
Salivary gland tumors are rare head and neck tumors constituting up to 6% of all head and neck neoplasms; despite being mostly benign, these tumors present in diverse histological subtypes, making them challenging to diagnose and treat. Our research aims to investigate the link between inflammation and tumorigenesis within the salivary glands based on the literature regarding the etiopathogenesis of benign salivary gland tumors. This scoping review was conducted following the PRISMA extension for scoping reviews and reporting guidelines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!